New oral anticoagulants [Neue orale antikoagulanzien]

被引：0
|
作者：
Stoberock K. [1 ]
Debus E.S. [1 ]
Larena-Avellaneda A. [1 ]
Kieback A. [1 ]
机构：
[1] Klinik und Poliklinik für Gefäßmedizin, Universitäres Herzzentrum Hamburg, Martinistr. 52
来源：
Gefässchirurgie | 2013年 / 18卷 / 7期
关键词：
Apixaban; Dabigatran; Rivaroxaban; Stroke; Thromboembolism;
D O I：
10.1007/s00772-013-1186-9
中图分类号：
学科分类号：
摘要：
In recent years the new oral anticoagulants dabigatran, rivaroxaban and apixaban have been approved for the prevention of stroke and thromboembolism and also rivaroxaban for therapy of thromboembolism. Extensive studies have shown that in comparison to conventional medications these new substances reduce the risk of severe bleeding, in particular intracranial hemorrhage as well as of stroke and thromboembolism despite a moderate increase in minor bleeding. In addition the administration offers considerable advantages while the disadvantages appear to be manageable. © Springer-Verlag 2013.
引用
收藏
页码：665 / 674
页数：9
相关论文
共 50 条
  • [21] Pharmacology of the new oral anticoagulants
    Dempfle, C. -E.
    HERZ, 2012, 37 (04) : 362 - 368
  • [22] New oral anticoagulants for patients with nonvalvular atrial fibrillation
    Holden, Amber
    Azimi, Nassir
    Forest, Christopher P.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2015, 28 (11): : 28 - 34
  • [23] Eligibility of patients with atrial fibrillation for new oral anticoagulants
    Moubarak, Ghassan
    Badenco, Nicolas
    Dreyfus, Julien
    Simion, Constantin
    Delos Paquet, Aurelie
    Cazeau, Serge
    Cador, Romain
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 165 (03) : 573 - 574
  • [24] New oral anticoagulants: focus on the safety
    Napalkov, D. A.
    Sokolova, A. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2014, 10 (04) : 444 - 447
  • [25] Safety assessment of new oral anticoagulants
    Gasso Sanchez, Amalia
    Real Campana, Jose Manuel
    Franco Sorolla, Jose Miguel
    Povar Marco, Bienvenido Javier
    Abad Sazatornil, Maria Reyes
    MEDICINA CLINICA, 2019, 152 (12): : 482 - 487
  • [26] Hepatotoxicity of New Oral Anticoagulants (NOACs)
    Evangelia Liakoni
    Alexandra E. Rätz Bravo
    Stephan Krähenbühl
    Drug Safety, 2015, 38 : 711 - 720
  • [27] Bleeding and antidotes in new oral anticoagulants
    Majeed, Ammar
    Schulman, Sam
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 191 - 202
  • [28] New oral anticoagulants and digestive hemorrhages
    Corberand, Damien
    Bredin, Christian
    Gizard, Emmanuel
    Sava, Claudia
    Rey, Philippe
    PRESSE MEDICALE, 2014, 43 (01): : 85 - 87
  • [29] New oral anticoagulants and emergency procedures
    Mertes, P. M.
    Sirieix, D.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2013, 32 (10): : 648 - 649
  • [30] New oral anticoagulants - a practical guide
    Ciurus, Tomasz
    Sobczak, Sebastian
    Cichocka-Radwan, Anna
    Lelonek, Malgorzata
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 12 (02) : 111 - 118
12345